Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era
The acronym CRAB summarizes the most typical clinical manifestations of multiple myeloma, these being hypercalcemia, renal failure, anemia, and bone disease. CRAB can be used to distinguish between active, symptomatic multiple myeloma and monoclonal gammopathy of undermined significance or smolderin...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-02-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | http://www.pagepress.org/journals/index.php/hr/article/view/6887 |
| _version_ | 1828047001354240000 |
|---|---|
| author | Aya Nakaya Shinya Fujita Atsushi Satake Takahisa Nakanishi Yoshiko Azuma Yukie Tsubokura Masaaki Hotta Hideaki Yoshimura Kazuyoshi Ishii Tomoki Ito Shosaku Nomura |
| author_facet | Aya Nakaya Shinya Fujita Atsushi Satake Takahisa Nakanishi Yoshiko Azuma Yukie Tsubokura Masaaki Hotta Hideaki Yoshimura Kazuyoshi Ishii Tomoki Ito Shosaku Nomura |
| author_sort | Aya Nakaya |
| collection | DOAJ |
| description | The acronym CRAB summarizes the most typical clinical manifestations of multiple myeloma, these being hypercalcemia, renal failure, anemia, and bone disease. CRAB can be used to distinguish between active, symptomatic multiple myeloma and monoclonal gammopathy of undermined significance or smoldering myeloma. The distinction is relevant not only for classification and diagnosis but also for therapy. CRAB factors influence the prognosis of multiple myeloma. However, it is unclear whether the presence of CRAB factors has an influence on the prognosis of myeloma treated with novel agents. In the current study, patients with hypercalcemia and bone disease showed a significantly worse prognosis, whereas anemia and renal failure showed no difference in survival. Novel agents used for treatment of patients with renal failure suggested a favorable outcome compared with conventional therapy. Bone disease was the most common factor and may have the strongest prognostic value in symptomatic myeloma patients using novel agents. |
| first_indexed | 2024-04-10T18:35:08Z |
| format | Article |
| id | doaj.art-adb75e343b6940b1b6b96bfbb58f2926 |
| institution | Directory Open Access Journal |
| issn | 2038-8322 2038-8330 |
| language | English |
| last_indexed | 2024-04-10T18:35:08Z |
| publishDate | 2017-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-adb75e343b6940b1b6b96bfbb58f29262023-02-02T01:55:38ZengMDPI AGHematology Reports2038-83222038-83302017-02-019110.4081/hr.2017.68873636Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent eraAya Nakaya0Shinya Fujita1Atsushi Satake2Takahisa Nakanishi3Yoshiko Azuma4Yukie Tsubokura5Masaaki Hotta6Hideaki Yoshimura7Kazuyoshi Ishii8Tomoki Ito9Shosaku Nomura10First Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataFirst Department of Internal Medicine, Kansai Medical University, HirakataThe acronym CRAB summarizes the most typical clinical manifestations of multiple myeloma, these being hypercalcemia, renal failure, anemia, and bone disease. CRAB can be used to distinguish between active, symptomatic multiple myeloma and monoclonal gammopathy of undermined significance or smoldering myeloma. The distinction is relevant not only for classification and diagnosis but also for therapy. CRAB factors influence the prognosis of multiple myeloma. However, it is unclear whether the presence of CRAB factors has an influence on the prognosis of myeloma treated with novel agents. In the current study, patients with hypercalcemia and bone disease showed a significantly worse prognosis, whereas anemia and renal failure showed no difference in survival. Novel agents used for treatment of patients with renal failure suggested a favorable outcome compared with conventional therapy. Bone disease was the most common factor and may have the strongest prognostic value in symptomatic myeloma patients using novel agents.http://www.pagepress.org/journals/index.php/hr/article/view/6887CRABsymptomatic myelomanovel agentconventional therapy |
| spellingShingle | Aya Nakaya Shinya Fujita Atsushi Satake Takahisa Nakanishi Yoshiko Azuma Yukie Tsubokura Masaaki Hotta Hideaki Yoshimura Kazuyoshi Ishii Tomoki Ito Shosaku Nomura Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era Hematology Reports CRAB symptomatic myeloma novel agent conventional therapy |
| title | Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era |
| title_full | Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era |
| title_fullStr | Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era |
| title_full_unstemmed | Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era |
| title_short | Impact of CRAB symptoms in survival of patients with symptomatic myeloma in novel agent era |
| title_sort | impact of crab symptoms in survival of patients with symptomatic myeloma in novel agent era |
| topic | CRAB symptomatic myeloma novel agent conventional therapy |
| url | http://www.pagepress.org/journals/index.php/hr/article/view/6887 |
| work_keys_str_mv | AT ayanakaya impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT shinyafujita impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT atsushisatake impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT takahisanakanishi impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT yoshikoazuma impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT yukietsubokura impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT masaakihotta impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT hideakiyoshimura impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT kazuyoshiishii impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT tomokiito impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera AT shosakunomura impactofcrabsymptomsinsurvivalofpatientswithsymptomaticmyelomainnovelagentera |